Biomarker Analysis Services for Leukemia
At Alfa Cytology, we offer specialized biomarker analysis services designed to accelerate leukemia research and therapeutic development. Our comprehensive biomarker panel encompasses key molecular and cellular indicators relevant to leukemia pathophysiology, enabling a deep understanding of disease mechanisms and progression. All services are exclusively focused on supporting drug discovery through preclinical development stages; we do not provide clinical diagnostic services.
Effective therapeutic intervention in leukemia begins with the robust discovery and identification of disease-relevant biomarkers. Alfa Cytology’s biomarker discovery services are foundational to drug development, enabling the identification of molecular targets and disease signatures. Our approach integrates high-throughput screening and rigorous validation processes, utilizing advanced analytical and computational tools to uncover and confirm candidate biomarkers with potential relevance to leukemia biology and therapeutic response.
Multi Omics: Our platform leverages state-of-the-art -omics technologies—including genomics, transcriptomics, proteomics, and epigenomics—for a holistic interrogation of biological systems. Through comprehensive multi-omics profiling, we identify DNA, RNA, protein, and metabolite biomarkers that illuminate the molecular landscape of leukemia. This approach enables the elucidation of key disease pathways such as aberrant tyrosine kinase signaling, dysregulated apoptosis, chromatin modification, and disrupted hematopoietic differentiation, providing actionable insights for therapeutic research.
Candidate Validation: We employ a suite of validation strategies to establish the association of candidate biomarkers with leukemia pathophysiology. Preliminary screening incorporates statistical, functional, and pathway-based analyses to prioritize candidates with strong biological rationale. Criteria for advancement include reproducibility, disease relevance, and correlation with established leukemia mechanisms. Only the most promising candidates undergo further evaluation to support their potential utility in preclinical therapeutic studies.
Diverse Technological Platforms: Alfa Cytology offers custom assay development tailored to the specific requirements of leukemia biomarker research. Our technological platforms are adaptable, supporting the integration of diverse analytical methods to address unique project needs. This flexibility ensures precise, sensitive, and reproducible measurement of a wide range of biomarker types across various sample formats.
Immunoassays: We develop and employ enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays, and multiplex immunoassay platforms for the quantification of protein biomarkers relevant to leukemia.
Mass Spectrometry: Our LC-MS/MS capabilities enable sensitive and specific detection of proteins, peptides, and small molecule biomarkers, supporting both targeted and discovery-based approaches.
Flow Cytometry: We utilize flow cytometry for high-throughput, multiparametric analysis of cell surface and intracellular markers, facilitating detailed immunophenotyping and functional studies.
Molecular Diagnostics: Our molecular platforms include PCR-based assays, digital PCR, and next-generation sequencing for the detection and quantification of nucleic acid biomarkers, including gene mutations, fusions, and expression signatures.
Histopathology And Imaging: We offer histopathological and advanced imaging analyses for spatial localization and quantification of biomarker expression within tissue samples, supporting morphological and molecular characterization.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with industry and regulatory guidelines. Validation parameters include sensitivity, specificity, accuracy, precision, linearity, and reproducibility. Comprehensive quality control measures are implemented at each stage to ensure data integrity, consistency, and reliability, supporting robust preclinical research outcomes.
Our quantitative analysis capabilities enable precise measurement of biomarker abundance and dynamics in biological samples. We provide comprehensive data analysis, normalization, and interpretation services, facilitating the integration of biomarker data into preclinical research pipelines.
Sample Analysis: We handle a diverse array of sample types, including cell lines, primary hematopoietic cells, bone marrow aspirates, and tissue lysates. Standardized protocols for sample preparation, processing, and storage are strictly followed to preserve biomarker integrity. Quality control steps are embedded throughout the workflow to monitor sample quality and analytical performance.
High Throughput Capabilities: Alfa Cytology employs multiplexed analytical platforms and automation to enable high-throughput biomarker analysis. This approach increases efficiency, reduces turnaround times, and conserves valuable samples by allowing simultaneous assessment of multiple biomarkers within a single run.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) | ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) encodes a protein tyrosine kinase that is involved in a variety of cellular processes, including regulation of cell differentiation, division, adhesion, and response to stress. The ABL1 protein contains SH2 and SH3 domains, which mediate interactions with other proteins, and a kinase domain responsible for its enzymatic activity. ABL1 is predominantly localized in the nucleus and cytoplasm, where it participates in signaling pathways that control the cell cycle and DNA repair. The activity of ABL1 is tightly regulated under normal physiological conditions, and dysregulation can contribute to oncogenic transformation. | ABL1 is used as a biomarker in the context of hematological malignancies, particularly chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). In these diseases, a chromosomal translocation t(9;22)(q34;q11) results in the formation of the BCR-ABL1 fusion gene, which produces a constitutively active tyrosine kinase. Detection of the BCR-ABL1 fusion transcript or protein is employed in diagnosis, monitoring of disease progression, and assessment of therapeutic response in affected patients. |
| BCL2 apoptosis regulator (BCL2) | BCL2 (B-cell lymphoma 2) is a key regulator of apoptosis, the programmed cell death process. The BCL2 protein is located on the outer mitochondrial membrane and acts to inhibit apoptosis by preventing the release of cytochrome c and other pro-apoptotic factors from mitochondria. It achieves this by binding and sequestering pro-apoptotic proteins, such as BAX and BAK, thereby maintaining mitochondrial integrity and promoting cell survival. BCL2 is a member of a larger family of proteins that includes both pro-apoptotic and anti-apoptotic members, and the balance between these proteins determines the susceptibility of a cell to apoptosis. | BCL2 expression is frequently assessed as a biomarker in various malignancies, particularly in hematological cancers such as follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Immunohistochemical detection of BCL2 protein can aid in the diagnosis and classification of lymphomas, helping to distinguish between different subtypes based on their BCL2 expression patterns. Additionally, BCL2 expression has been studied for its association with prognosis and response to therapy in certain cancers. |
| BCR activator of RhoGEF and GTPase (BCR) | The BCR (breakpoint cluster region) protein functions as a regulator of small GTPases, acting as a GTPase-activating protein (GAP) for the Rac family of Rho GTPases and as a guanine nucleotide exchange factor (GEF) for RhoA. Through these activities, BCR modulates cytoskeletal organization, cell migration, and signal transduction pathways. BCR is also involved in the regulation of cell proliferation and differentiation. In hematopoietic cells, BCR plays a role in maintaining normal cellular signaling. The N-terminal region of BCR possesses serine/threonine kinase activity, while its C-terminal region contains domains responsible for GTPase regulation. | BCR is most notably recognized in the context of the BCR-ABL1 fusion gene, which arises from the t(9;22)(q34;q11) chromosomal translocation known as the Philadelphia chromosome. The presence of the BCR-ABL1 fusion transcript serves as a key molecular marker for the diagnosis and monitoring of chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). Detection of BCR-ABL1 is used to assess disease burden, monitor response to therapy, and detect minimal residual disease. The native BCR protein itself is less commonly used as a direct biomarker outside the context of its fusion with ABL1. |
| Janus kinase 2 (JAK2) | Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase that plays a central role in the signaling pathways of various cytokine receptors, including those for erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor. Upon cytokine binding to their respective receptors, JAK2 becomes activated through trans-phosphorylation and subsequently phosphorylates specific tyrosine residues on the receptor. This creates docking sites for signal transducers and activators of transcription (STAT) proteins, which are then phosphorylated by JAK2, leading to their dimerization, nuclear translocation, and regulation of gene expression. JAK2-mediated signaling is critical for hematopoiesis, immune function, and cell proliferation. | JAK2 is commonly assessed as a biomarker in the context of myeloproliferative neoplasms (MPNs), particularly through the detection of the JAK2 V617F point mutation. The presence of this mutation is frequently observed in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Detection of JAK2 mutations can aid in the differential diagnosis of these hematological disorders, inform prognosis, and guide therapeutic decisions, including the use of JAK2 inhibitors. |
| RUNX family transcription factor 1 (RUNX1) | RUNX family transcription factor 1 (RUNX1) is a transcription factor that plays a critical role in the regulation of hematopoiesis. It is involved in the differentiation and proliferation of hematopoietic stem cells and is essential for the development of definitive hematopoietic lineages, including myeloid, lymphoid, and megakaryocytic cells. RUNX1 functions as part of a core-binding factor (CBF) complex, binding to specific DNA sequences to regulate the expression of target genes involved in cell cycle control, apoptosis, and lineage commitment. Mutations or chromosomal translocations affecting RUNX1 can disrupt normal hematopoietic differentiation and are implicated in the pathogenesis of various hematological malignancies. | RUNX1 is used as a biomarker primarily in the context of hematological diseases. Chromosomal translocations involving RUNX1, such as t(8;21)(q22;q22), which generates the RUNX1-RUNX1T1 fusion gene, are identified in a subset of acute myeloid leukemia (AML) cases and are used for diagnostic classification, prognostic assessment, and disease monitoring. Additionally, RUNX1 mutations are detected in myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (ALL), and familial platelet disorder with predisposition to myeloid malignancy (FPDMM), providing information relevant to disease characterization and risk stratification. |
| fms related receptor tyrosine kinase 3 (FLT3) | Fms related receptor tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase family. It is primarily expressed on hematopoietic progenitor cells and plays a key role in the regulation of hematopoiesis. Upon binding its ligand (FLT3 ligand), FLT3 undergoes dimerization and autophosphorylation, activating downstream signaling pathways such as PI3K/AKT, RAS/MAPK, and STAT5. These pathways promote cell survival, proliferation, and differentiation within the hematopoietic system. Aberrant activation of FLT3, often due to mutations, can disrupt normal cell development and contribute to oncogenesis. | FLT3 is frequently assessed in the context of acute myeloid leukemia (AML), where internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain (TKD) of the FLT3 gene are among the most common genetic alterations. Detection of FLT3 mutations is used to provide prognostic information, as certain mutations are associated with disease progression and outcomes. FLT3 mutation status is also used to guide therapeutic decisions, including the use of FLT3-targeted inhibitors in clinical management. |
| homeobox A9 (HOXA9) | Homeobox A9 (HOXA9) is a member of the homeobox family of transcription factors, which play critical roles in regulating gene expression during embryonic development and cellular differentiation. HOXA9 is involved in the patterning of the anterior-posterior axis and is essential for the proper development of the hematopoietic system, particularly in the regulation of hematopoietic stem and progenitor cell proliferation and differentiation. In adult tissues, HOXA9 expression is typically low, but it can be reactivated in certain pathological conditions. | HOXA9 has been studied as a biomarker in various malignancies, most notably in acute myeloid leukemia (AML), where its overexpression has been associated with specific genetic subtypes and disease prognosis. Elevated HOXA9 expression has also been reported in other cancers, such as lung and ovarian cancers. Its expression levels are frequently assessed in research settings to aid in disease classification, risk stratification, and to explore potential therapeutic targets. |
| lysine methyltransferase 2A (KMT2A) | Lysine methyltransferase 2A (KMT2A), also known as mixed-lineage leukemia 1 (MLL1), is a histone methyltransferase that primarily catalyzes the methylation of histone H3 at lysine 4 (H3K4). This post-translational modification is associated with transcriptionally active chromatin and plays a critical role in the regulation of gene expression. KMT2A is essential for normal hematopoiesis, embryonic development, and the maintenance of stem cell pluripotency. It functions as part of a large multiprotein complex and regulates the expression of multiple target genes, including homeobox (HOX) gene clusters, which are important for developmental processes. | KMT2A is utilized as a biomarker in the context of hematological malignancies, particularly acute leukemias. Chromosomal rearrangements involving KMT2A, such as translocations, are frequently identified in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The presence of KMT2A gene rearrangements is used in the diagnosis, classification, and risk stratification of these leukemias. Detection of KMT2A alterations can aid in guiding clinical management and monitoring minimal residual disease. |
| platelet derived growth factor receptor beta (PDGFRB) | Platelet derived growth factor receptor beta (PDGFRB) is a cell surface tyrosine kinase receptor that binds members of the platelet-derived growth factor (PDGF) family. Upon ligand binding, PDGFRB undergoes dimerization and autophosphorylation, initiating intracellular signaling cascades such as the PI3K/AKT, Ras/MAPK, and PLCγ pathways. These signaling events regulate a variety of cellular processes, including proliferation, migration, differentiation, and survival, particularly in mesenchymal cells such as fibroblasts, pericytes, and smooth muscle cells. PDGFRB plays a critical role in embryonic development, angiogenesis, wound healing, and maintenance of vascular integrity. | PDGFRB expression and activation have been studied as biomarkers in several pathological contexts. In oncology, aberrant PDGFRB expression or genetic alterations, such as translocations or mutations, have been detected in certain hematologic malignancies (e.g., myeloproliferative neoplasms) and solid tumors, where they may correlate with disease subtype or progression. In addition, PDGFRB has been investigated as a biomarker for stromal activation and angiogenesis in tumor microenvironments. Beyond cancer, PDGFRB has been explored as a marker in fibrotic diseases and vascular disorders, reflecting its role in mesenchymal cell activation and vascular remodeling. |
| tet methylcytosine dioxygenase 2 (TET2) | TET2 (tet methylcytosine dioxygenase 2) is an enzyme that plays a critical role in epigenetic regulation through the process of DNA demethylation. TET2 catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA, which is a key step in the active DNA demethylation pathway. This enzymatic activity influences gene expression by modulating the methylation status of cytosine residues, thereby affecting chromatin structure and the transcriptional activity of various genes. TET2 function is important for normal hematopoiesis and cellular differentiation. Loss-of-function mutations in TET2 have been associated with altered epigenetic landscapes and dysregulated gene expression. | Alterations in TET2, particularly loss-of-function mutations, have been identified in various hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other myeloid neoplasms. The presence of TET2 mutations is used as a molecular biomarker in the diagnostic evaluation, classification, and prognostic assessment of these disorders. Detection of TET2 mutations can assist in distinguishing between different subtypes of myeloid neoplasms and may provide information relevant to disease progression and therapeutic response. |
Explore Research Opportunities with Alfa Cytology. Our biomarker research services offer comprehensive support for leukemia therapeutic development, leveraging advanced analytical platforms and a multi-omics approach to accelerate drug discovery in preclinical settings. Please note that all biomarkers discussed are research targets only and are not claimed as validated or mandatory markers. Our services are strictly focused on exploratory research and preclinical development, and we maintain complete scientific objectivity in all collaborative efforts.
We invite you to connect with Alfa Cytology to discuss collaborative opportunities in biomarker research for leukemia. Our work emphasizes the exploratory and scientific nature of biomarker discovery, focusing on knowledge exchange and preclinical research. Let’s advance leukemia research together through objective, data-driven collaboration.
Make Order
Experimental Scheme
Implementation
Conclusion
Solutions For Leukemia
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.